* Evolent Health Inc EVH.N EVH is expected to show a
rise in
quarterly revenue when it reports results on November 2.
* The Arlington Virginia-based company is expected to
report a
60.2% increase in revenue to $356.42 million from $222.47
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. The company's guidance on
August 2 2022, for the period ended September 30, was for
revenue between $343.00 million and $363.00 million.
* Refinitiv's mean analyst estimate for Evolent Health Inc
is for
earnings of 12 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evolent
Health
Inc is $45, above its last closing price of $31.81.
The company's guidance on August 2 2022 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD343 million and
USD29 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 0.05 0.05 0.10 Beat 105.9
Mar. 31 2022 0.00 0.00 0.12 Beat 6,100
Dec. 31 2021 0.00 0.01 0.08 Beat 860.4
Sep. 30 2021 -0.02 -0.03 -0.03 Met 8.7
Jun. -0.03 -0.04 -0.02 Beat 44.4
30 2021
Mar. 31 2021 -0.05 -0.06 -0.01 Beat 84.6
Dec. 31 2020 -0.05 -0.05 -0.01 Beat 78.4
Sep. 30 2020 -0.04 -0.04 -0.03 Beat 31.8
This summary was machine generated November 1 at 00:40 GMT. All
figures in US dollars unless otherwise stated